|View printer-friendly version|
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
The company has taken steps to protect the safety of its employees while working to ensure the sustainability of its business operations and development programs as the COVID-19 pandemic continues to evolve. Beginning in mid-March,
SB 11285 is currently being evaluated as an IV-administered monotherapy in a Phase 1a/1b multicenter, dose escalation clinical trial in patients with advanced solid tumors.
“We are pleased that the Safety Review Committee for our IV SB 11285 Phase 1a/1b has recommended the dose escalation in our ongoing study and we have proceeded to the dosing of the first patient in the next planned higher dose level,” said
About Spring Bank Pharmaceuticals
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.